The US Food and Drug Administration (FDA) has approved Boehringer’s Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). Jascayd is an oral treatment option for adult patients with IPF, becoming the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!